Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “buy” rating reissued by stock analysts at Chardan Capital in a report released on Friday.
The analysts wrote, “We now raise our PT to $175, after: (1) increasing the patisiran probability of success to 97%, and (2) lowering the Alnylam WACC to 8% to reflect further RNAi therapeutics platform de-risking. We now update our Alnylam patient-based and other models to reflect recent positives, while consolidating views from recent Chardan macro research (e.g. on novel lipid-lowering therapies). (See Figures 3-7.) Notably, a near- best-case safety and efficacy profile emerged from the pivotal APOLLO trial (as discussed in our 20 September 2017 research); and, Alnylam proceeded to file patisiran in an expeditious fashion. We thus newly model a 97% probability of success (POS) for patisiran and $1.77 billion in 2030E risk-adjusted franchise sales (patisiran and follow ons). We now increase the POS of givosiran, to 80% ($540 million in 2030E sales) from 40% in our previous model, given the product’s progress ahead of our expectations.””
A number of other research firms also recently commented on ALNY. B. Riley dropped their price target on shares of Alnylam Pharmaceuticals to $220.00 and set a “buy” rating on the stock in a research report on Wednesday, November 8th. Ladenburg Thalmann Financial Services restated a “buy” rating and set a $146.00 price target (up from $90.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 21st. Sanford C. Bernstein restated a “buy” rating and set a $135.00 price target (up from $94.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 21st. Needham & Company LLC restated a “buy” rating and set a $152.00 price target (up from $125.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, November 3rd. Finally, FBR & Co assumed coverage on shares of Alnylam Pharmaceuticals in a research report on Monday, October 30th. They set a “buy” rating and a $150.00 price target on the stock. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $121.20.
Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at $123.99 on Friday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.83 and a current ratio of 9.83. The stock has a market cap of $12,190.00, a PE ratio of -23.62 and a beta of 2.98. Alnylam Pharmaceuticals has a one year low of $35.98 and a one year high of $147.63.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.11). The firm had revenue of $17.10 million for the quarter, compared to analyst estimates of $28.15 million. Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The company’s revenue for the quarter was up 24.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.21) earnings per share. equities research analysts predict that Alnylam Pharmaceuticals will post -5.29 earnings per share for the current fiscal year.
In other news, VP Michael Mason sold 36,745 shares of the business’s stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $131.59, for a total transaction of $4,835,274.55. Following the sale, the vice president now owns 6,352 shares in the company, valued at $835,859.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Laurie Keating sold 6,249 shares of the business’s stock in a transaction that occurred on Wednesday, December 20th. The shares were sold at an average price of $121.20, for a total transaction of $757,378.80. Following the sale, the senior vice president now owns 17,749 shares in the company, valued at approximately $2,151,178.80. The disclosure for this sale can be found here. Insiders sold a total of 274,075 shares of company stock worth $35,356,089 over the last quarter. Insiders own 4.30% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. Livforsakringsbolaget Skandia Omsesidigt acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $165,000. Fayerweather Charles acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $230,000. Watch Point Trust Co acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $235,000. Segall Bryant & Hamill LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $235,000. Finally, Security National Bank of SO Dak acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $247,000. Institutional investors and hedge funds own 88.39% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Alnylam Pharmaceuticals’ (ALNY) “Buy” Rating Reaffirmed at Chardan Capital” was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://ledgergazette.com/2018/01/19/alnylam-pharmaceuticals-alny-buy-rating-reaffirmed-at-chardan-capital.html.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.